Speaker: Dr. Andrew Loblaw
Original Date: Thursday November 6, 2014
In October, 2014, the Canadian Task Force on Preventative Health Care, a body that did not include a single urologist, oncologist or prostate cancer patient, recommended against PSA testing.
The immediate reaction from Prostate Cancer Canada and virtually every recognized Canadian expert in the field was to condemn this report. Many of the statements released concluded that if governments and insurance companies accept this recommendation, more Canadian men will die unnecessarily.
This Expert Angle webinar with noted radiation oncologist and researcher Dr. Andrew Loblaw highlighted the benefits of PSA testing. In particular, Dr. Loblaw discusses:
- the importance of active surveillance and its adoption in Canada
- the need to measure baseline PSA to determine prostate cancer risk
- the use of modeling data to augment cohort data
Dr. Andrew Loblaw is a Radiation Oncologist, Clinician Scientist and Associate Professor in the Departments of Radiation Oncology and Health Policy Management and Evaluation at the University of Toronto. He has a Masters in Clinical Epidemiology from the University of Toronto and is a graduate of the Royal College’s Clinician Investigator Program. Dr. Loblaw’s clinical practice focuses on prostate cancer. He has a research interest in improving outcomes for men with prostate cancer, particularly determining the optimal timing of salvage androgen deprivation therapy, and the outcomes of active surveillance and image-guided radiotherapy. Dr. Loblaw is an Ontario Association of Radiation Oncology Clinician Scientist and a Scientist at the Sunnybrook Research Institute. He is the North American Editor for Clinical Oncology and the Co-Chair of the American Society of Clinical Oncology’s Genitourinary Advisory Group and Co-Chair of the GU group for Cancer Care Ontario’s Program in Evidence-Based Care. He has authored over 150 peer-reviewed papers and has been awarded grant funding of over $12 million dollars.